Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Humacyte (HUMA) and Tectonic Therapeutic (TECX) with...

Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Tectonic Therapeutic (TECX)

The latest update is out from Humacyte ( ($HUMA) ). On June 10, 2026, Humacyte reported positive top-line interim results from its Phase 3 V012 tri...

Humacyte Announces Positive Phase 3 Dialysis Access Results

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM). Ve...

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)

Humacyte ( ($HUMA) ) just unveiled an announcement. On May 4, 2026, Humacyte, Inc. disclosed that it had received a notice from Nasdaq after its co...

Humacyte Regains Nasdaq Compliance With Minimum Bid Price

In a report released today, Stephen Baxter from Wells Fargo maintained a Hold rating on Humana, with a price target of $227.00. According to TipRan...

Humana (HUM) Receives a Hold from Wells Fargo

An announcement from Humm Group Limited ( ($AU:HUM) ) is now available. Humm Group Limited has formalised a comprehensive Securities Trading Policy...

Humm Group Tightens Governance With New Securities Trading Policy

Humana AB ( ($SE:HUM) ) has issued an announcement. Humana AB’s Annual General Meeting approved the 2025 financial statements and confirmed a divid...

Humana AGM Approves Dividend, Share Issuance Mandate and Capital Changes

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Humana (HUM) and HCA Healthcare (HCA). Humana (HUM) In a report r...

Analysts Conflicted on These Healthcare Names: Humana (HUM) and HCA Healthcare (HCA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Climb Bio (CLYM), Humacyte (HUMA) and Phathom Pharma...

Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), Humacyte (HUMA) and Phathom Pharmaceuticals (PHAT)

The SPDR S&P 500 ETF Trust ($SPY) gained 0.39% today, May 22, due to lower Treasury yields, hope for progress in U.S.-Iran talks, and strong corpor...

SPDR S&P 500 ETF Trust (SPY) Daily Update, 5/22/2026

The latest announcement is out from Humana AB ( ($SE:HUM) ). Humana AB and Samhällsbyggnadsbolaget i Norden have agreed to sell an elderly care hom...

Humana Sells Elderly Care Property to Cut Debt and Refocus Capital

The SPDR S&P 500 ETF Trust ($SPY) gained 0.2% today, May 21, as falling oil and energy prices eased inflation worries. Hopes for progress in U.S.-I...

Current Quarter	$6.17	Next Quarter	$-0.3
Current Year	$9.04	Next Year	$14.97
QoQ Growth	-104.9%	YoY Growth	+65.6%
3Y EPS CAGR	N/A	Target Price	$300.26
Consensus	Buy	Upside	-16.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HUM	$360.65	-0.37%	3.57M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HUM	$360.65	-0.4%	3.57M
3
4
5
6

HUM

HUM

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Humana Inc. Data in Excel

Get Humana Inc. Data in Excel